MMRF Molecular Profiling Protocol
Knowing your myeloma subtype is the key to achieving your best treatment outcome. The most accurate way to define your subtype is by having your myeloma genome sequenced – and the MMRF is here to help!
We offer free genomic sequencing via our Molecular Profiling Protocol, or MPP, to relapsed myeloma patients at our MMRC sites. We are the only myeloma foundation that offers this service to myeloma patients. Few cancer centers outside of our MMRC network offer this service. Our ability to offer this testing sets us apart, and is yet another example of our long-standing pioneering efforts around precision medicine in myeloma.
What does it mean to have your genome sequenced?
In this test, researchers look at the DNA in your normal cells and compare it to the DNA in your myeloma cells. They look for changes in the DNA of your myeloma cells that may play in a role in your myeloma. Find out more about genomic sequencing here.
What is the MPP?
MPP is a study where myeloma patients who have relapsed on their current therapy within 36 months (or within 12 months if the patient is transplant ineligible) can consent to have their myeloma genome sequenced at one of our participating MMRC sites.
How does the study work?
If you are eligible and consent to join the study, your blood and bone marrow samples will be collected and sequenced to look for DNA changes. The results will be returned to your doctor within 10-14 days.
Who pays for the genomic sequencing?
If you are eligible, the MMRF will pay for your genomic sequencing. Your insurance will not be charged, and no costs will come out of pocket.
What do the results mean?
Your doctor will receive a report from the sequencing lab that lists any genomic alterations that are found. Your doctor will contact you and tell you if your myeloma contains an “actionable” mutation, or DNA change. That means that the mutation may be treated with a therapy that is targeted against that mutation. Currently the MMRC has three targeted agent trials open, with more scheduled to open later this year and moving forward in 2019.
What happens if I do not have an “actionable’ mutation?
This sequencing information still helps your doctor decide which treatment might be most appropriate based on your disease subtype.
How do I find out if I am eligible to enroll in the MPP?
For more information, please speak to one of our nurse patient navigators:
866-603-6628 or email@example.com